Skip to content
value.today

Interleukin Genetics Inc.

Total raised
$26 M
4 rounds on record
Latest round
$6 M
Jul 2016
First round on record
Jun 2012
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Interleukin Genetics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2016$6 MNo. 4$2 to $10 million

Interleukin Genetics Inc.: Raise no. 4, Jul 2016

Investors in this round

10 investors had bought by the notice of Aug 11, 2016: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Interleukin Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth S. Kornman · Executive Officer, Director
  • Mark B. Carbeau · Executive Officer, Director
  • Stephen C. DiPalma · Executive Officer
  • Dayton C. Misfeldt · Director
  • James C. Weaver · Director
  • Joseph M. Landstra · Director
  • Lionel C. Carnot · Director
  • Roger C. Colman · Director
  • William C. Mills III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stephen DiPalma, Interim Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 11, 2016. Read the notice at the SEC.

equity, optionsSEC
Dec 2014$5 MNo. 3$2 to $10 million

Interleukin Genetics Inc.: Raise no. 3, Dec 2014

Investors in this round

9 investors had bought by the notice of Jan 8, 2015: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Interleukin Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$155,250
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth Kornman · Executive Officer, Director
  • Stephen DiPalma · Executive Officer
  • Dayton Misfeldt · Director
  • James Weaver · Director
  • Joseph Landstra · Director
  • Lionel Carnot · Director
  • Roger Colman · Director
  • William Mills III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BTIG, LLC (CRD 122225) · San Francisco, CaliforniaSold in CA, CT, FL, IL, MA, MD, NY, UT

Signed by Stephen DiPalma, Interim Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 8, 2015. Read the notice at the SEC.

equity, optionsSEC
May 2013$12 MNo. 2$10 to $50 million

Interleukin Genetics Inc.: Raise no. 2, May 2013

Investors in this round

10 investors had bought by the notice of May 30, 2013: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Interleukin Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $17 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$780,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eliot M. Lurier · Executive Officer
  • Kenneth S. Kornman · Executive Officer, Director
  • Scott M. Snyder · Executive Officer
  • Dayton C. Misfeldt · Director
  • Goran C. Jurkovic · Director
  • James S. Weaver · Director
  • Lionel C. Carnot · Director
  • Roger C. Colman · Director
  • William C. Mills, III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BTIG, LLC (CRD 122225) · San Francisco, CaliforniaSold in CA, IL, MD, MI, NY

Remarks in the notice

  • On fees: “BTIG, LLC received $780,000 cash and warrants to purchase 2,295,082 shares of common stock, at an exercise price of $0.2745 per share, exercisable following shareholder approval of increase in authorized shares; expires 7 years from exercise date.”

Signed by Eliot Lurier, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed May 30, 2013. Read the notice at the SEC.

equity, optionsSEC
Jun 2012$3 MNo. 1$2 to $10 million

Interleukin Genetics Inc.: Raise no. 1, Jun 2012

Investors in this round

1 investor had bought by the notice of Jul 11, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Interleukin Genetics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$210,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lewis H. Bender · Executive Officer, Director
  • Catherine H. Ehrenberger · Director
  • James H. Weaver · Director
  • Mary H. Chowning · Director
  • Roger H. Colman · Director
  • Thomas H. Curran · Director
  • William H. Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BTIG, LLC (CRD 122225) · San Francisco, CaliforniaSold in MI

Remarks in the notice

  • On fees: “BTIG, LLC received $210,000 cash compensation and warrants to purchase 437,158 shares of Interleukin's common stock, at an exercise price of $0.2745 per share, exercisable immediately.”

Signed by Lewis H. Bender, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 11, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Interleukin Genetics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2016).

    SEC Form D · Aug 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2016

That is all the official record says: Interleukin Genetics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Interleukin Genetics Inc.
InvestorKindAmountRoundRoleSource
Delta Dental Plan of Michigan, Inc.Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2012)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Interleukin Genetics Inc.
NameRoleNamed in
Kenneth S. KornmanExecutive officerAug 2016
Mark B. CarbeauExecutive officerAug 2016
Stephen C. DiPalmaExecutive officerAug 2016
Kenneth KornmanExecutive officerJan 2015
Stephen DiPalmaExecutive officerJan 2015
Eliot M. LurierExecutive officerMay 2013
Scott M. SnyderExecutive officerMay 2013
Lewis H. BenderExecutive officerJul 2012
Dayton C. MisfeldtDirectorAug 2016
James C. WeaverDirectorAug 2016
Joseph M. LandstraDirectorAug 2016
Kenneth S. KornmanDirectorAug 2016
Lionel C. CarnotDirectorAug 2016
Mark B. CarbeauDirectorAug 2016
Roger C. ColmanDirectorAug 2016
William C. Mills IIIDirectorAug 2016
Dayton MisfeldtDirectorJan 2015
James WeaverDirectorJan 2015
Joseph LandstraDirectorJan 2015
Kenneth KornmanDirectorJan 2015
Lionel CarnotDirectorJan 2015
Roger ColmanDirectorJan 2015
William Mills IIIDirectorJan 2015
Goran C. JurkovicDirectorMay 2013
James S. WeaverDirectorMay 2013
William C. Mills, IIIDirectorMay 2013
Catherine H. EhrenbergerDirectorJul 2012
James H. WeaverDirectorJul 2012
Lewis H. BenderDirectorJul 2012
Mary H. ChowningDirectorJul 2012
Roger H. ColmanDirectorJul 2012
Thomas H. CurranDirectorJul 2012
William H. MillsDirectorJul 2012